Ropivacaine is an aminoamide local anesthetic drug marketed by AstraZeneca under the trade name Naropin. It exists as a racemate of its S- and R-enantiomers, although the marketed form is supplied only as the purified S-enantiomer.
Ropivacaine is indicated in adult patients for the induction of regional or local anesthesia for surgery or acute pain management.
Department of Anesthesiology, General Hospital of Ningxia Medical University, Yinchuan, Ningxia, China
CHU Amiens, Amiens, France
Akutmottagningen US Östergötland, Linköping, Östergötland, Sweden
Department of Anesthesiology,Peking University Third Hospital, Beijing, Beijing, China
Peking University Third Hosptial, Beijing, China
National and Kapodistrian University of Athens, Athens, Attiki, Greece
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
Rothman Orthopaedic Institute, Philadelphia, Pennsylvania, United States
Aga Khan University Hospital, Karachi, Sind, Pakistan
Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang, China
Affiliated Hospital of Nantong University, Nantong, Jiangsu, China
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.